Psoriasis Clinical Trial

Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis

Summary

The purpose of this study is to determine an optimal abatacept dosing regimen for the treatment of active arthritis due to psoriatic arthritis in patients who have had a prior inadequate response to disease-modifying antirheumatic drugs, including methotrexate and tumor necrosis factor alpha-blockade compounds.

View Eligibility Criteria

Eligibility Criteria

Key Inclusion Criteria:

Meeting classification criteria for psoriatic arthritis for a duration of disease of at least 3 months
Prior failure (inefficacy or intolerance) of therapy with disease-modifying antirheumatic drugs; if patient had prior failure of methotrexate, he or she must have been taking at least 15 mg per week for at least 2 months
If recent failure(inefficacy or intolerance) of a tumor necrosis factor α-blockade compound, participant must be washed out prior to first dose: 56 days for infliximab and 28 days for etanercept and adalimumab
Disease activity as defined by a tender joint count of ≥3, swollen joint count of ≥3, and clinically detectable synovitis at screening and Day 01 (prior to infusion)
Active psoriasis with a qualifying target lesion ≥2 cm in diameter
Able to undergo magnetic resonance imaging
Use of appropriate birth control by women of child bearing potential (WOCBP)

Key Exclusion Criteria:

WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 10 weeks after the last dose of investigational product
Women who are pregnant or breastfeeding or who plan to become pregnant or to start breastfeeding during the duration of the study
Women with a positive pregnancy test on enrollment or prior to investigational product administration.
Participants scheduled for or anticipating joint replacement surgery.
Those with a recent history of clinically significant drug or alcohol abuse
Concomitant illness that in the investigator's opinion is likely to require systemic glucocorticosteroid therapy during the study (for example: moderate to severe asthma)
Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematologic, pulmonary, cardiac, neurologic, ophthalmologic, or cerebral disease.
Unwillingness or inability to undergo screening based on current local or country guidelines/standards to evaluate the presence of cancer
Cancer within the last 5 years
Current malignancy or signs of possible malignancy detected by screening procedures for which the workup to exclude malignancy has not been completed or malignancy cannot be excluded
At risk for or history (within 3 years) of tuberculosis
Any serious bacterial infection within the last 3 months, not treated and resolved with antibiotics, or any chronic bacterial infection (such as, but not limited to, chronic pyelonephritis, osteomyelitis, and bronchiectasis)
Evidence of active or latent bacterial or viral infection infections at the time of potential enrollment
Herpes zoster or cytomegalovirus resolving less than 2 months prior to signing informed consent
Receipt of any live vaccines within 3 months of the anticipated first dose of study medication or anticipation of the need for a live vaccine at any time during and for 3 months after the duration of the study

Long-term period participants: Must have met eligibility criteria for short-term period and completed short-term (24-week) period of the study

Study is for people with:

Psoriasis

Phase:

Phase 2

Estimated Enrollment:

191

Study ID:

NCT00534313

Recruitment Status:

Terminated

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 43 Locations for this study

See Locations Near You

Rheumatology Associates Of North Alabama
Huntsville Alabama, 35801, United States
Desert Medical Advances
Palm Desert California, 92260, United States
Stanford University School Of Medicine
Palo Alto California, 94304, United States
Boling Clinical Trials
Upland California, 91786, United States
Joao Nascimento
Bridgeport Connecticut, 06606, United States
New England Research Associates, Llc
Trumbull Connecticut, 06611, United States
Sarasota Arthritis Research Center
Sarasota Florida, 34239, United States
Clinical Pharmacology Study Group
Worcester Massachusetts, 01610, United States
Justus Fiechtner, Md, Mph
Lansing Michigan, 48910, United States
St. Paul Rheumatology P.A.
Eagan Minnesota, 55121, United States
Midwest Arthritis Center
Kalamazoo Minnesota, 49048, United States
Arthritis Clinic & Carolina Bone & Joint, Pa
Charlotte North Carolina, 28210, United States
Deaconess Hospital
Cincinnati Ohio, 45219, United States
Health Research Of Oklahoma
Oklahoma City Oklahoma, 73103, United States
Altoona Center For Clinical Research
Duncansville Pennsylvania, 16635, United States
Rheumatic Disease Associates, Ltd.
Willow Grove Pennsylvania, 19090, United States
Chase, Walter F.
Austin Texas, 78705, United States
Seattle Rheumatology Associates
Seattle Washington, 98104, United States
Arthritis Northwest
Spokane Washington, 99204, United States
Local Institution
Capital Federal Buenos Aires, 1015, Argentina
Local Institution
Rosario Santa Fe, 2000, Argentina
Local Institution
Santa Fe , 3000, Argentina
Local Institution
Cairns Queensland, 4872, Australia
Local Institution
Maroochydore Queensland, 4558, Australia
Local Institution
Fitzroy, Melbourne Victoria, 3065, Australia
Local Institution
Hasselt , 3500, Belgium
Local Institution
Leuven , 3000, Belgium
Local Institution
St. John'S Newfoundland and Labrador, A1B 3, Canada
Local Institution
Montreal Quebec, H2L 1, Canada
Local Institution
Trois-Rivieres Quebec, G8Z 1, Canada
Local Institution
Quebec , G1W 4, Canada
Local Institution
Chambray Les Tours , 37170, France
Local Institution
Lille , 59037, France
Local Institution
Montpellier Cedex 5 , 34295, France
Local Institution
Frankfurt/Main , 60590, Germany
Local Institution
Hamburg , 22081, Germany
Local Institution
Hildesheim , 31134, Germany
Local Institution
Napoli , 80131, Italy
Local Institution
Potenza , 85100, Italy
Local Institution
Reggio Emilia , 42100, Italy
Local Institution
Amsterdam , 1105 , Netherlands
Local Institution
Lillehammer , 2609, Norway
Local Institution
Panorama Western Cape, 7500, South Africa
Local Institution
A Coruna , 15006, Spain

How clear is this clinincal trial information?

Study is for people with:

Psoriasis

Phase:

Phase 2

Estimated Enrollment:

191

Study ID:

NCT00534313

Recruitment Status:

Terminated

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider